Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
Front Pharmacol
.
2022 Nov 10:13:1072353.
doi: 10.3389/fphar.2022.1072353.
eCollection 2022.
Authors
Ana Blas-García
1
2
3
,
Francisco Javier Cubero
3
4
5
Affiliations
1
Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain.
2
FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana), Valencia, Spain.
3
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
4
Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain.
5
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
PMID:
36438803
PMCID:
PMC9687366
DOI:
10.3389/fphar.2022.1072353
No abstract available
Keywords:
NAFLD; NASH; gut; liver; microbiome; therapy.
Publication types
Editorial